Evidence map›Paper›PMID 30034678›Full record

ArticleMedChemComm2017

Targeting quinolone- and aminocoumarin-resistant bacteria with new gyramide analogs that inhibit DNA gyrase.

Katherine A Hurley, Thiago M A Santos, Molly R Fensterwald, Madhusudan Rajendran, Jared T Moore, Edward I Balmond, Brice J Blahnik, Katherine C Faulkner, Marie H Foss, Victoria A Heinrich and 8 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in MedChemComm, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 11 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 1 country.

Katherine A HurleyDepartment of Biochemistry, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Thiago M A SantosDepartment of Biochemistry, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Molly R FensterwaldDepartment of Chemistry, University of California-Davis, Davis, California, USA.
Madhusudan RajendranDepartment of Biochemistry, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Jared T MooreDepartment of Chemistry, University of California-Davis, Davis, California, USA.
Edward I BalmondDepartment of Chemistry, University of California-Davis, Davis, California, USA.
Brice J BlahnikDepartment of Biochemistry, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Katherine C FaulknerDepartment of Biochemistry, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Marie H FossDepartment of Biochemistry, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Victoria A HeinrichDepartment of Biochemistry, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Matthew G LammersDepartment of Biochemistry, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Lucas C MooreDepartment of Chemistry, University of California-Davis, Davis, California, USA.
Gregory D ReynoldsDepartment of Biochemistry, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Galen P Shearn-NanceDepartment of Chemistry, University of California-Davis, Davis, California, USA.
Brian A StearnsInception Sciences, Inc., San Diego, California, USA.
Zi W YaoDepartment of Chemistry, University of California-Davis, Davis, California, USA.
Jared T ShawDepartment of Chemistry, University of California-Davis, Davis, California, USA.
Douglas B WeibelDepartment of Biochemistry, University of Wisconsin-Madison, Madison, Wisconsin, USA.
University of Wisconsin–Madison · USUniversity of California, Davis · USIncept (United States) · US

Funding

Revisiting the bacterial cell wall as a target for new antibioticsDP2OD008735 · OD · UNIVERSITY OF WISCONSIN-MADISON · PI WEIBEL, DOUGLAS BENJAMIN · 2011 to 2011
$2.3M
NIH HHS DP2 OD008735
6 · The paper itself

Abstract

Bacterial DNA gyrase is an essential type II topoisomerase that enables cells to overcome topological barriers encountered during replication, transcription, recombination, and repair. This enzyme is ubiquitous in bacteria and represents an important clinical target for antibacterial therapy. In this paper we report the characterization of three exciting new gyramide analogs-from a library of 183 derivatives-that are potent inhibitors of DNA gyrase and are active against clinical strains of gram-negative bacteria (

Identifiers

PMID30034678
PMCPMC6051542
OpenAlexW2593539445

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.